Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. BRZE
2. TTAN
3. CHYM
4. USO
5. ASO
6. QCOM
7. IRT
8. SPY
9. EVMN
10. AAPL

Go back to Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 212.26 -0.24 (0.11%)
Previous Close $212.50    52 Week High $333.65 
Open $210.50    52 Week Low $223.02 
Day High $213.48    P/E 27.18 
Day Low $209.00    EPS $7.81 
Volume 200,157       

Sagebrush Gold Ltd. (NASDAQ: SAGE) Delayed: 8.68 --0 (-0%)
Previous Close $8.68    52 Week High $62.64 
Open $8.68    52 Week Low $26.28 
Day High $8.68    P/E N/A 
Day Low $8.68    EPS $-0.94 
Volume 107,095